UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

Form 10-Q

(Mark One)

☒	QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
	For the quarterly period ended June 30, 2020
or
☐	TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
	For the transition period from  _____________ to _____________

 

Commission File Number: 333-207765

    

ACRO BIOMEDICAL CO., LTD.

(Exact name of registrant as specified in its charter)

 

Nevada		47-1950356
(State or other jurisdiction of incorporation or organization)		(IRS Employer Identification No.)

 

12175 Visionary Way, Suite 1160; Fishers, Indiana 46038

(Address of principal executive offices)

  

(317) 286-6788

(Registrant’s telephone number, including area code)

   

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.  ☐ Yes     ☒ No

  

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). ☒ Yes     ☐ No

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a small reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

   

Large accelerated filer	☐	Accelerated filer	☐
Non-accelerated filer	☒	Smaller reporting company	☒
		Emerging growth company	☐

        

If an emerging growth company, indicate by a check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act ☐

 

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act): ☐ Yes     ☒ No

 

Securities registered pursuant to Section 12(b) of the Exchange Act: None

 

Indicate the number of shares outstanding of each of the issuer’s classes of common stock, as of the latest practicable date: 47,760,000 shares of common stock on August 14, 2020.

     

ACRO BIOMEDICAL CO., LTD.

 

INDEX

 

			Page No.
Part I: Financial Information
Item 1:	Financial Statements			4
	Balance Sheets as of June 30, 2020 and December 31, 2019 (Unaudited)			4
	Statements of Operations for the three and six months ended June 30, 2020 and 2019 (Unaudited)			5
	Statement of Changes in Stockholders’ Equity for the three and six months ended June 30, 2020 and 2019 (Unaudited)			6
	Statements of Cash Flows for the six months ended June 30, 2020 and 2019 (Unaudited)			7
	Notes to Unaudited Financial Statements			8
Item 2:	Management’s Discussion and Analysis of Financial Condition and Results of Operations			12
Item 3:	Quantitative and Qualitative Disclosures about Market Risk			16
Item 4:	Controls and Procedures			16
Part II: Other Information
Item 6:	Exhibits			17

   

2

Table of Contents

     

FORWARD-LOOKING STATEMENTS

 

This report contains forward-looking statements regarding our business, financial condition, results of operations and prospects. Words such as “expects,” “anticipates,” “intends,” “plans,” “believes,” “seeks,” “estimates” and similar expressions or variations of such words are intended to identify forward-looking statements, but are not deemed to represent an all-inclusive means of identifying forward-looking statements as denoted in this report. Additionally, statements concerning future matters are forward-looking statements.

 

Although forward-looking statements in this report reflect the good faith judgment of our management, such statements can only be based on facts and factors currently known by us. Consequently, forward-looking statements are inherently subject to risks and uncertainties and actual results and outcomes may differ materially from the results and outcomes discussed in or anticipated by the forward-looking statements. Factors that could cause or contribute to such differences in results and outcomes include, without limitation, those specifically addressed under the headings “Forward Looking Statements,” “Risks Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in our transition report on Form 10-K for the year ended December 31, 2019, in “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in this Form 10-Q and information contained in other reports that we file with the SEC. You are urged not to place undue reliance on these forward-looking statements, which speak only as of the date of this report.

 

We file reports with the SEC. The SEC maintains a website (www.sec.gov) that contains reports, proxy and information statements, and other information regarding issuers that file electronically with the SEC.

 

We undertake no obligation to revise or update any forward-looking statements in order to reflect any event or circumstance that may arise after the date of this report, except as required by law. Readers are urged to carefully review and consider the various disclosures made throughout the entirety of this quarterly report, which are designed to advise interested parties of the risks and factors that may affect our business, financial condition, results of operations and prospects.

   

3

Table of Contents

  

ITEM 1: FINANCIAL STATEMENTS

ACRO BIOMEDICAL CO., LTD.

Balance Sheets

(Unaudited)

 

		June 30,				December 31,
		2020				2019
ASSETS
Current Assets
Cash and cash equivalents		$	381			$	911
Inventories			938,000				878,560
Purchase deposit for inventory			12,000				-
Prepaid expenses			7,000				-
Total Current Assets			957,381				879,471
Operating lease right of use asset			36,682				48,425
Security deposit			4,230				4,230
TOTAL ASSETS		$	998,293			$	932,126
LIABILITIES AND STOCKHOLDERS’ EQUITY
Current Liabilities
Accounts payable and accrued expenses		$	1,072			$	23,834
Deferred revenue			20,000				37,464
Due to related parties			123,594				26,279
Operating lease liabilities - current			26,602				23,964
Total Current Liabilities			171,268				111,541
Operating lease liabilities - noncurrent			10,000				22,346
TOTAL LIABILITIES			181,268				133,887
Stockholders’ Equity
Preferred stock: 25,000,000 authorized; $0.001 par value; no shares issued and outstanding			-				-
Common stock: 100,000,000 authorized; $0.001 par value; 47,760,000 shares issued and outstanding as of June 30, 2020 and December 31, 2019			47,760				47,760
Additional paid-in capital			873,049				871,680
Accumulated deficit			(103,784	)			(121,201	)
Total Stockholders’ Equity			817,025				798,239
TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY		$	998,293			$	932,126

 

The accompanying notes are an integral part of these unaudited financial statements. 

 

4

Table of Contents

 

ACRO BIOMEDICAL CO., LTD.

Statements of Operations

(Unaudited)

 

		Three Months Ended								Six Months Ended
		June 30,								June 30,
		2020				2019				2020				2019
Revenues		$	-			$	-			$	687,964			$	-
Cost of revenues			-				-				528,560				-
Gross profit			-				-				159,404				-
Operating expenses
Selling, general and administrative			62,771				68,092				140,618				282,858
Total operating expenses			62,771				68,092				140,618				282,858
Income (loss) from operations			(62,771	)			(68,092	)			18,786				(282,858	)
Other expense
Interest expense - related party			928				609				1,369				717
Total other expenses			928				609				1,369				717
Income (loss) before income tax credit			(63,699	)			(68,701	)			17,417				(283,575	)
Income taxes credit			-				(17,877	)			-				(63,001	)
Net income (loss)		$	(63,699	)		$	(50,824	)		$	17,417			$	(220,574	)
Basic and dilutive income (loss) per share of common stock		$	(0.00	)		$	(0.00	)		$	0.00			$	(0.00	)
Weighted average number of shares of common stock outstanding			47,760,000				47,760,000				47,760,000				47,760,000

  

The accompanying notes are an integral part of these unaudited financial statements.

 

5

Table of Contents

    

ACRO BIOMEDICAL CO., LTD.

Statements of Changes in Stockholders’ Equity

(Unaudited)

 

																		Additional								Total
		Preferred Stock								Common Stock								Paid in				Accumulated				Stockholders’
		Shares				Amount				Shares				Amount				Capital				Deficit				Equity
Balance, December 31, 2019			-			$	-				47,760,000			$	47,760			$	871,680			$	(121,201	)		$	798,239
Imputed interest on related party loans			-				-				-				-				441				-				441
Net income			-				-				-				-				-				81,116				81,116
Balance, March 31, 2020			-			$	-				47,760,000			$	47,760			$	872,121			$	(40,085	)		$	879,796
Imputed interest on related party loans			-				-				-				-				928				-				928
Net loss			-				-				-				-				-				(63,699	)			(63,699	)
Balance, June 30, 2020			-			$	-				47,760,000			$	47,760			$	873,049			$	(103,784	)		$	817,025

 

																		Additional				Retained earnings				Total
		Preferred Stock								Common Stock								Paid in				(Accumulated				Stockholders’
		Shares				Amount				Shares				Amount				Capital				Deficit )				Equity
Balance, December 31, 2018			-			$	-				47,760,000			$	47,760			$	869,697			$	250,403			$	1,167,860
Imputed interest on related party loans			-				-				-				-				108				-				108
Net loss			-				-				-				-				-				(169,750	)			(169,750	)
Balance, March 31, 2019			-			$	-				47,760,000			$	47,760			$	869,805			$	80,653			$	998,218
Imputed interest on related party loans			-				-				-				-				609				-				609
Net loss			-				-				-				-				-				(50,824	)			(50,824	)
Balance, June 30, 2019			-			$	-				47,760,000			$	47,760			$	870,414			$	29,829			$	948,003

 

he accompanying notes are an integral part of these unaudited financial statements.

 

6

Table of Contents

   

ACRO BIOMEDICAL CO., LTD.

Statements of Cash Flows

(Unaudited)

 

		Six Months Ended
		June 30,
		2020				2019
CASH FLOWS FROM OPERATING ACTIVITIES
Net income (loss)		$	17,417			$	(220,574	)
Adjustments to reconcile net income (loss) to net cash used in operating activities:
Stock based compensation			-				148,395
Imputed interest - related parties			1,369				717
Deferred tax asset			-				10,070
Change of ROU and lease liabilities			2,035				-
Adjustment of income tax for payable			-				(73,071	)
Changes in operating assets and liabilities:
Inventories			(59,440	)			-
Purchase deposit for inventory			(12,000	)			-
Prepaid expenses			(7,000	)			(6,000	)
Accounts payable and accrued expenses			(22,762	)			2,108
Income tax payable			-				(19,156	)
Deferred revenue			(17,464	)			20,000
Net cash used in operating activities			(97,845	)			(137,511	)
CASH FLOWS FROM FINANCING ACTIVITIES
Advances from related parties			97,315				100,135
Net cash provided by financing activities			97,315				100,135
Net change in cash and cash equivalents			(530	)			(37,376	)
Cash and cash equivalent at beginning of period			911				37,607
Cash and cash equivalent at end of period		$	381			$	231
SUPPLEMENTAL CASH FLOW INFORMATION:
Cash paid for income taxes		$	-			$	19,156
Cash paid for interest		$	-			$	-

 

The accompanying notes are an integral part of these unaudited financial statements.

 

7

Table of Contents

  

ACRO BIOMEDICAL CO., LTD.

Notes to Financial Statements

June 30, 2020

(Unaudited)

 

NOTE 1 - ORGANIZATION AND DESCRIPTION OF BUSINESS

 

Acro Biomedical Co., Ltd. (the “Company”) is a Nevada corporation incorporated on September 24, 2014 under the name Killer Waves Hawaii, Inc., which was changed to Acro Biomedical Co., Ltd. on January 30, 2017. The Company’s business is the sale of cordyceps related products and, to a significantly lesser extent, metallothionein MT-3 elizer, a protein that in powder form is used in health supplements. Cordyceps is a fungus that is used in traditional Chinese medicine. The Company has not sold metallothionein MT-3 elizer since the quarter ended March 31, 2018, and its present inventory and the purchase deposit for inventory are for cordyceps related products. Although the Company intends to conduct research and development on its own proprietary products based on cordyceps sinensis, as of June 30, 2020, it has not commenced such activities, and it can provide no assurance that it will be able to conduct such activities.

 

NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

 

Unaudited Interim Financial Statements

 

The accompanying unaudited interim financial statements have been prepared in accordance with generally accepted accounting principles in the United States of America for interim financial information and with Rule 8-03 of Regulation S-X. Accordingly, the unaudited interim financial statements do not include all of the information and footnotes required by generally accepted accounting principles for complete financial statements. Notes to the unaudited interim financial statements that would substantially duplicate the disclosures contained in the audited financial statements for the year ended December 31, 2019 have been omitted; these unaudited interim financial statements should be read in conjunction with the audited financial statements and the footnotes thereto for the fiscal year ended December 31, 2019 included within the Company’s transition report on Form 10-K.

 

In the opinion of management, all adjustments consisting of normal recurring entries necessary for a fair statement of the periods presented for: (a) the financial position; (b) the result of operations; and (c) cash flows, have been made in order to make the unaudited interim financial statements presented not misleading. The results of operations for such interim periods are not necessarily indicative of operations for a full year.

 

Use of Estimates

 

The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements. The estimates and judgments will also affect the reported amounts for certain revenues and expenses during the reporting period. Actual results could differ from these good faith estimates and judgments.

 

Revenue Recognition

 

Revenues are recognized when control of the promised goods or services are transferred to a customer, in an amount that reflects the consideration that the Company expects to receive in exchange for those goods or services. The Company applies the following five steps in order to determine the appropriate amount of revenue to be recognized as it fulfills its obligations under each of its agreements:

 

	·	identify the contract with a customer;
	·	identify the performance obligations in the contract;
	·	determine the transaction price;
	·	allocate the transaction price to performance obligations in the contract; and
	·	recognize revenue as the performance obligation is satisfied.

  

8

Table of Contents

   

Under these criteria, the Company generally recognizes revenue when its products are delivered to customers in accordance with the written sales terms.

 

Inventories

 

Inventories consist of finished goods. Inventories are valued at the lower of cost or net realizable value. The Company determines cost on the basis of first-in, first-out methods. The Company periodically reviews inventories for obsolescence and any inventories identified as obsolete are written down or written off. Although the Company believes that the assumptions it uses to estimate inventory write-downs are reasonable, future changes in these assumptions could provide a significantly different result. No inventory markdown was recorded for the six months ended June 30, 2020 and 2019.

 

Net Income (Loss) Per Share of Common Stock

 

The Company has adopted ASC Topic 260, “Earnings per Share” which requires presentation of basic earnings per share on the face of the statements of operations for all entities with complex capital structures and requires a reconciliation of the numerator and denominator of the basic earnings per share computation. In the accompanying financial statements, basic loss per share is computed by dividing net loss by the weighted average number of shares of common stock outstanding during the year. Diluted earnings per share is computed by dividing net income by the weighted average number of shares of common stock and potentially dilutive outstanding shares of common stock during the period to reflect the potential dilution that could occur from common shares issuable through contingent share arrangements, stock options and warrants unless the result would be antidilutive. There were no potentially dilutive shares of common stock outstanding for the six months ended June 30, 2020 and 2019.

 

COVID 19

 

Since our products are purchased by customers in Taiwan and Hong Kong who sold to their customers in the People’s Republic of China (the “PRC”), our business was impacted by the effects of the COVID-19 pandemic and the actions taken by the governments of the PRC, the Republic of China and Hong Kong. Since we had no sales in the three months ended June 30, 2020 or the three and six months ended June 30, 2019 and modest sales in the six months ended June 30, 2020 (all of which were generated in the three months ended March 31, 2020), as well as sales only in the last quarter of 2019 during the year ended December 31, 2019, we cannot predict the effect of COVID-19 on our business. A prolonged outbreak could have a material adverse impact on financial results and business operations of the Company. The Company believes that the COVID19 pandemic and the government results significantly contributed to its lack of sales in the three months ended June 30, 2020.

 

NOTE 3 - GOING CONCERN

 

The accompanying unaudited financial statements have been prepared assuming that the Company will continue as a going concern, which contemplates the realization of assets and the liquidation of liabilities in the normal course of business. The Company had minimal cash as of June 30, 2020 and did not generate cash from its operation for the six months ended June 30, 2020 and has no sales in the three months ended June 30, 2020 and, during the year ended December 31, 2019, only had sales in the fourth quarter. These factors, among others, raise substantial doubt about the Company’s ability to continue as a going concern. The financial statements do not include any adjustments that might result from the outcome of this uncertainty.

 

The Company proposes to fund operations through sales of its products and equity financing arrangements. The Company plans to introduce a marketing effort to market its products, however, it cannot give any assurance as to its ability to implement a marketing program or to generate revenue or net income from these efforts. Further, the Company did not have any sales during the three months ended June 30, 2020, does not have any agreements or understanding with respect to any financing and, because of the lack of sales and the absence of any active trading market for its common stock, its financial condition and its lack of an operating history, the Company may not be able to raise funds for capital expenditures, working capital and other cash requirements. The Company’s ability to implement its marketing plan may be affected by the COVID-19 pandemic and actions taken by governments to address the pandemic as well as political events and legislation in Hong Kong. If the Company cannot generate revenue from its products, it may not be able to continue in its business.

   

9

Table of Contents

 

NOTE 4 - RELATED PARTY TRANSACTIONS

 

At June 30, 2020 and December 31, 2019, the Company owed $123,594 and $26,279 to a stockholder who is not a 5% stockholder for non-interest-bearing advances made to or on behalf of the Company, respectively. These advances are due on demand.

 

During the six months ended June 30, 2020 and 2019, the stockholder paid expenses of $97,315 and $80,135 on behalf of the Company and the stockholder made a loan of $0 and $20,000 to the Company, respectively.

 

The Company has imputed interest at the rate of 4% on the advances made to the Company in the amount of $1,369 and $717 during the six months ended June 30, 2020 and 2019, and $928 and $609 during the three months ended June 30, 2020 and 2019, respectively.

 

NOTE 5 - LEASES

 

On December 27, 2019, the Company entered into a new lease agreement to rent a storage facility in Hong Kong for a two-year term at HK$16,500 (approximately $2,115) per month. A stockholder paid HK$33,000 (approximately $4,230) as a security deposit and HK$16,500 (approximately $2,115) as prepaid rent on behalf of the Company.

 

In accordance with ASC 842, the Company recognized operating lease ROU assets and lease liabilities as follows;

 

		June 30,				December 31,
		2020				2019
Operating lease ROU asset		$	36,682			$	48,425

 

		June 30,				December 31,
Operating lease liabilities		2020				2019
Current portion		$	26,602			$	23,964
Non-current portion			10,000				22,346
Total		$	36,602			$	46,310

 

Future minimum lease payments under operating leases at June 30, 2020 were as follows:

 

Remainder of 2020		$	14,845
2021			22,787
Thereafter			-
Total			37,632
Less Imputed interest			(1,030	)
Operating lease liabilities			36,602

 

The Company recognized total lease expense of approximately $12,571 and $15,120 for the six months ended June 30, 2020 and 2019, respectively, primarily related to operating rent lease costs paid to lessors.

 

NOTE 6 - CONCENTRATION

 

Revenue

 

During the six months ended June 30, 2020, all revenue was derived from one customer.

 

Purchases

 

During the six months ended June 30, 2020, we purchased inventory from one supplier.

   

We did not purchase any inventory during the three and six months ended June 30, 2019 and three months ended June 30, 2020. During the three months ended June 30, 2020, we received delivery of inventory which had been purchased during the three months ended March 31, 2020.

 

10

Table of Contents

 

NOTE 7 - INCOME TAX

 

The reconciliation of income tax expense (credit) at the statutory federal income tax rate of 21% to the Company’s effective income taxes is as follows:

 

		Six Months Ended
		June 30,
		2020				2019
Income tax expense (credit) at statutory rate		$	3,658			$	(59,551	)
Income tax adjustment
Expense not deductible in current period			-				69,319
Imputed interest			287				302
Adjustment of prior year income tax			-				(73,071	)
Operating losses utilized			(3,945	)			-
Income tax expense (credit)		$	-			$	(63,001	)

 

Net deferred tax assets consist of the following components:

 

		June 30,				December 31,
		2020				2019
Operating loss carry forward		$	39,248			$	39,248
Operating losses utilized			(3,945	)			-
Valuation allowance			(35,303	)			(39,248	)
Deferred tax asset		$	-			$	-

 

NOTE 8 - SUBSEQUENT EVENTS

 

The Company has evaluated subsequent events that have occurred after the date of the balance sheet through the date of issuance of these unaudited financial statements and determined that no subsequent event requires recognition or disclosure to the unaudited financial statements except as set forth below.

 

On August 7, 2020, the Company’s sole director adopted, and on August 8, 2020, the Company’s stockholders approved, by a written consent signed by the Company’s sole director, who holds 62.8% of the Company’s common stock, the Company’s 2020 Long-Term Incentive Plan, pursuant to which a maximum of 12,000,000 shares of common stock may be issued pursuant to restricted stock grants, incentive stock options, non-qualified stock options and other equity-based incentives may be granted.  Awards under the plan may be issued to employees, directors of the Company or its affiliates or consultants. As of the date of the issuance of these unaudited financial statements, no options, stock grants or other equity-based incentives had been granted pursuant to the plan.

    

11

Table of Contents

  

Item 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

 

The following discussion and analysis of financial condition and results of operations should be read in conjunction with our financial statements and related notes included elsewhere in this report. This discussion contains forward-looking statements that involve risks, uncertainties and assumptions. See “Forward-Looking Statements.”

 

Overview

 

Since January 30, 2017, following a change of control, we have been engaged in the business of developing and marketing nutritional products that promote wellness and a healthy lifestyle. Our business to date has involved the purchase of products from three suppliers in the Republic of China and the sale of these products to three unrelated customers, one of which accounted for all of our sales in the quarters ended March 31, 2020, which were our only sales in the six months ended June 30, 2020, and December 31, 2019, which were our only sales in the year ended December 31, 2019. We did not have any sales during the three months ended June 30, 2020 or first three quarters of the year ended December 31, 2019. We sell product in bulk to companies who may use our products as ingredients in their products or sell the products they purchase from us to their own customers.

 

All of our sales to date have been sales of cordyceps related products and, in the quarter ended March 31, 2018, metallothionein MT-3 elizer. Cordyceps is a fungus that is used in traditional Chinese medicine. Cordyceps sinensis has been described as a medicine in old Chinese medical books and Tibetan medicine. It is a rare combination of a caterpillar and a fungus and found at altitudes above 4500m in Sikkim. Our present inventory is for cordyseps products. The encoded protein in metallothionein MT-3 is a growth inhibitory factor, and reduced levels of the protein are observed in the brains of individuals with some metal-linked neurodegenerative disorders such as Alzheimer’s disease. We have not sold metallothionein MT-3 elizer since the quarter ended March 31, 2018, and we do not have any orders for metallothionein MT-3 elizer. We cannot assure you that we will be able to sell metallothionein MT-3 elizer in the future. We may also seek to market other products which we see as complimentary to our present products; however, we have not entered into negotiations with respect to the distribution of other products and we cannot assure you that we will be able to market any other products.

  

All of our revenue for the six months ended June 30, 2020 represents sales to one customer which were made during the three months ended March 31, 2020. There were no sales during the three months ended June 30, 2020. We believe that our failure to sell products in the three months ended June 30, 2020 resulted substantially from the COVID – 19 pandemic and actions taken by governments to address the pandemic. We believe our failure to generate sales reflects a downturn in the market in the PRC for cordyseps products as well as the political conditions in Hong Kong, and we cannot assure you that the market will improve. We also cannot assure you the political instability in Hong Kong will not affect our sales, since our customers in 2017 and 2018 were Hong Kong based customers who sold their products in the People’s Republic of China (the “PRC”) and none of these customers has made purchases from us since the quarter ended December 31, 2018.  We cannot assure you that these factors will not affect our ability to generate revenues in the future and, to the extent that any of these factors affects our ability to generate revenue, we may not be able to continue in business.

 

At present, we have no full-time employees. Our only employee is our chief executive officer who works for us on a part-time basis, and all of our sales to date have been made by our chief executive officer. We plan to develop a marketing program pursuant to which we will seek to:

 

	·	market raw materials to customers, primarily in Hong Kong, who would use our products as an ingredient on their products;
	·	enter into agreements with customers pursuant to which we would develop and supply products which include our ingredients and which meet the specifications of the customer;
	·	develop one or more products which we would sell to retail outlets which would sell our products to their customers or sell the products directly to retail customers as on-line sales.

     

12

Table of Contents

  

We do not presently have either a marketing staff or any manufacturing facilities. We intend to develop a marketing staff by hiring a marketing manager and engaging independent sales representatives or hiring sales and marketing and sales personnel or a combination of independent representatives and sales staff. We cannot assure you that we will be able to engage the necessary qualified personnel or to implement an effective marketing program.

 

We face significant risks in implementing our business plan including, but not limited to, our ability to raise the necessary financing either through the sale of debt or equity securities or through a loan facility, our ability to increase our customer base and supply chain, our ability to increase our gross margins, our ability to hire and retain qualified research and development, marketing and administrative personnel, our ability to develop products and to market in the United States and other western markets any products we may develop, our ability to comply with any government regulations relating to the manufacture, distribution and marketing any products we develop. We cannot assure you that we can or will develop any products or generate revenue or profits in the future.

 

Although our business plan initially contemplated that we would conduct research and development on our own proprietary products based on cordyceps sinensis, to date we have neither commenced such activities nor take any preliminary steps with respect to such activities. We do not presently have the funds necessary for us to engage in such activities, and we cannot assure you that we will be able to commence any research and development activities or that any such activities that we may undertake will be successful.

 

We require funds for our operations. At June 30, 2020, we had $381cash and cash equivalents, $938,000 of inventory of cordyceps products. Although we may seek to raise funds in the equity market, we have no agreements or understandings with respect to any funding and we can give no assurance as to the availability or terms of any such financing. Because of our financial condition, the lack of sales in the three months ended June 30, 2020 or first nine months of 2019 and only modest sales in the fourth quarter of 2019 and the first quarter of 2020, our reliance of sales primarily of one product, along with the absence of an active market for our stock and our market capitalization in relation to our financial performance, together with risk related to the COVID-19 pandemic and the political and legal situation in Hong Kong, it may be difficult for us to raise funds in the equity market, and, if we are able to raise funds our stockholders may suffer significant dilution.

 

To the extent that we implement our business plan, we anticipate that we will incur marketing and other expenses without any assurance that such expenses will generate any significant revenue or net income. Because of our cash position, we may use equity-based compensation for our employees and independent contractors. In August 2020, we adopted our 2020 long-term incentive plan, pursuant to which up to 12,000,000 shares can be issued. In order to pay cash expenses, we may have to rely on loans from stockholders or related parties, although we do not have any agreements or understandings at this time.

 

Effects of COVID-19

  

Since our products are purchased by customers in Hong Kong as one ingredient of a product to be sold to their customers, our business has been and may continue to be impacted by the effects of the COVID-19 pandemic and the actions taken by the governments of the PRC, Hong Kong and the Republic of China (“Taiwan”) as they effect manufacturers and their customers. Since we had modest sales in the three months ended March 31, 2020 as well as the year ended December 31, 2019, with sales in only the last quarter of 2019, we cannot predict the effect of COVID-19 on our business. A prolonged outbreak could have a material adverse impact on our financial results and business operations. Factors relating to COVID-19 which significantly contributed to our lack of revenue in the three months ended June 30, 2020, may affect us and the market for our products include, but are not limited to, the following.

 

	·	The effect of COVID-19 on the ability of our customers and potential customers to manufacture products.
	·	The financial health of our potential customers.
	·	Since our customers use our products as an ingredient in their products, the inability of the customer to obtain other ingredients may affect their willingness or ability to purchase our product.
	·	The ability of our customers to ship their products to China and the ability of their customers to distribute product to retail markets.

    

13

Table of Contents

      

	·	The willingness or ability of the ultimate purchasers in the PRC and any other countries to which our customers sell products to purchase products with our ingredients and their perception as to whether the products may have beneficial effects to them.
	·	The extent to which any quarantine which may be imposed affects the willingness or ability of consumers to purchase products with our ingredients.
	·	The perceived benefit, if any, to consumers of products with our ingredients.
	·	The extent to which the purchase of products with our ingredients is a low priority item for a population whose disposable income may have decreased as a result of COVID-19 and the steps taken by governments to curb the spread of infection.

 

Results of Operations

 

Three and Six Months Ended June 30, 2020 and 2019.

 

For the three months ended June 30, 2020, we had no revenue, operating expenses of $62,771, primarily professional fees relating to our status as a public company, interest expense of $928 and a net loss of $63,699, or $(0.00) per share (basic and diluted).

 

For the three months-ended June 30, 2019, we had no revenues, operating expenses of $68,092, primarily professional fees related to our status as a public company, interest expense of $609, a loss before income taxes of $68,701, an income tax credit of $17,877, and a net loss of $50,824 or $(0.00) per share (basic and diluted).

 

For the six months ended June 30, 2020, we had revenue of $687,964, representing sales of cordyceps products from one customer. Our cost of revenue was $528,560, our gross profit was $159,404, and our gross margin was 23.17%.  Our operating expenses were $140,618, primarily professional fees relating to our status as a public company, our interest expense was $1,369 and we had net income of $17,417, or $0.00 per share (basic and diluted).

 

For the six months ended June 30, 2019 we had no revenue, operating expenses of $282,858, primarily stock-based compensation to consultants of $148,395, and professional fees relating to our status as a public company, interest expense of $717, a loss before income tax credit of $283,575, an income tax credit of $63,001, and a net loss of $220,574, or $(0.00) per share (basic and diluted).

 

Because of our dependence on a few customers, one of which accounted for all of our sales since January 1, 2019, our revenue in any quarter is dependent upon both the timing of orders from customers and the delivery of products from our suppliers.

 

Liquidity and Capital Resources

 

The following table summarizes our changes in working capital from December 31, 2019 to June 30, 2020:

 

		June 30, 2020				December 31, 2019				Change				% Change
Current assets		$	957,381			$	879,471			$	77,910				8.9	%
Current liabilities		$	171,268			$	111,541			$	59,727				53.5	%
Working capital		$	786,113			$	767,930			$	18,183				2.4	%

 

Our principal current asset is inventory, which was $938,000 at June 30, 2020 and $878,560 at December 31, 2019. To the extent that we are not able to sell our inventory, our working capital will be materially impaired.

    

14

Table of Contents

 

The following table summarizes our cash flows for the six months ended June 30, 2020 and 2019: 

 

		Six Months Ended June 30,
		2020				2019
Cash (used in) operating activities		$	(97,845	)		$	(137,511	)
Cash provided by financing activities			97,315				100,135
Cash and cash equivalents end of period			381				231

 

Cash used in operating activities of $97,845 for the six months ended June 30, 2020 reflected primarily our net income of $17,417 decreased primarily by an increase in inventory of $59,440, a decrease in accounts payable and accrued expenses of $22,762, and a decrease of deferred revenue of $17,464 and an increase in prepaid expenses of $12,000.

 

Cash used by operating activities of $137,511 for the six months ended June 30, 2019 reflected primarily our net loss of $220,574, decreased primarily by stock-based compensation of $148,395, deferred revenue of $20,000 and a deferred tax asset of $10,070, and increased by an adjustment in income tax payable $73,071 and income tax payable of $19,156.

 

Our cash used in financing activities of $97,315 for the six months ended June 30, 2020 and $100,135 for the six months ended June 30, 2019 represented advances from related parties.

 

Going Concern

 

The accompanying unaudited financial statements have been prepared assuming that we will continue as a going concern, which contemplates the realization of assets and the liquidation of liabilities in the normal course of business. We had minimal cash as of June 30, 2020 and did not generate cash from its operation for the six months ended June 30, 2020 and we had no sales in the three months ended June 30, 2020 and, during the year ended December 31, 2019, we only had sales in the fourth quarter. These factors, among others, raise substantial doubt about our ability to continue as a going concern. The financial statements do not include any adjustments that might result from the outcome of this uncertainty.

 

We propose to fund operations through sales of its products and equity financing arrangements. We plan to introduce a marketing effort to market our products, however, we cannot give any assurance as to our ability to implement a marketing program or to generate revenue or net income from these efforts. Further, we did not have any sales during the three months ended June 30, 2020, do not have any agreements or understanding with respect to any financing and, because of the lack of sales and the absence of any active trading market for our common stock, our financial condition and our lack of an operating history, we may not be able to raise funds for capital expenditures, working capital and other cash requirements. Our ability to implement our proposed marketing plan may be affected by the COVID-19 pandemic and actions taken by governments to address the pandemic as well as political events and legislation in Hong Kong. If we cannot generate revenue from our products, we may not be able to continue in its business.

 

Critical Accounting Policy and Estimates

 

Our critical accounting policies are disclosed in Note 2 or Notes to Financial Statements.

 

Recent Accounting Pronouncements

 

Management has considered all recent accounting pronouncements. Our management believes that these recent pronouncements will not have a material effect on our financial statements.

 

Off-Balance Sheet Arrangements

 

We do not have any off-balance sheet arrangements that have or are reasonably likely to have a current or future effect on our financial condition, changes in financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital resources that is material to investors.

    

15

Table of Contents

 

Item 3: QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

 

Smaller reporting companies are not required to provide the information required by this item. 

 

Item 4: CONTROLS AND PROCEDURES

 

Evaluation of Disclosure Controls and Procedures

 

We conducted an evaluation of the effectiveness of our disclosure controls and procedures (“Disclosure Controls”), as defined by Rules 13a-15(e) and 15d-15(e) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), as of June 30, 2020, the end of the period covered by this Quarterly Report on Form 10-Q. The Disclosure Controls evaluation was done under the supervision and with the participation of management, including our chief executive officer and chief financial officer, which positions are held by the same person and who is our only employee who does not work for us on a full-time basis. There are inherent limitations to the effectiveness of any system of disclosure controls and procedures. Accordingly, even effective disclosure controls and procedures can only provide reasonable assurance of achieving their control objectives. Based upon this evaluation, our chief executive officer and chief financial officer, concluded that, due to the inadequacy of our internal controls over financial reporting, our sole employee being our chief executive and financial officer and our limited internal audit function, our disclosure controls were not effective as of June 30, 2020, such that the information required to be disclosed by us in reports filed under the Exchange Act is (i) recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms and (ii) accumulated and communicated to the president and treasurer, as appropriate to allow timely decisions regarding disclosure.

 

Changes in Internal Control over Financial Reporting

 

As reported in our transition report on Form 10-K for the period ended December 31, 2019, management has determined that our internal controls contain material weaknesses due to the absence of segregation of duties, as well as lack of qualified accounting personnel and excessive reliance on third party consultants for accounting, financial reporting and related activities. The lack of any separation of duties, with the same person, who is our only employee who serves as both chief executive officer and chief financial officer, who is our sole director and who does not have an accounting background and serves on a part-time basis, makes it unlikely that we will be able to implement effective internal controls over financial reporting in the near future.

 

During the period ended June 30, 2020, there was no change in our internal control over financial reporting (as such term is defined in Rule 13a-15(f) under the Exchange Act) that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

     

16

Table of Contents

 

PART II – OTHER INFORMATION

 

Item 6: EXHIBITS

 

Exhibits

 

Exhibit Number		Description of Exhibits
31.1		Section 302 Certificate of Chief Executive Officer and Principal Financial Officer.
32.1		Section 906 Certificate of Chief Executive Officer and Principal Financial Officer.
101.INS		XBRL Instance Document
101.SCH		XBRL Taxonomy Schema Document
101.CAL		XBRL Taxonomy Calculation Linkbase Document
101.DEF		XBRL Taxonomy Definition Linkbase Document
101.LAB		XBRL Taxonomy Label Linkbase Document
101.PRE		XBRL Taxonomy Presentation Linkbase Document

     

17

Table of Contents

  

SIGNATURE

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

 

	ACRO BIOMEDICAL CO., LTD.
Dated: August 19, 2020	By:	/s/ Pao-Chi Chu
		Pao-Chi Chu
		Chief Executive Officer and Chief Financial Officer

  

    

ACRO BIOMEDICAL CO., LTD. Reports 12/16/2016 - 10-K 01/16/2018 - 10-K 12/28/2018 - 10-K 01/07/2020 - 10-K 04/02/2021 - 10-K 05/13/2016 - 10-Q 08/03/2016 - 10-Q 02/14/2017 - 10-Q 05/22/2017 - 10-Q 08/11/2017 - 10-Q 02/14/2018 - 10-Q 08/01/2018 - 10-Q 08/14/2018 - 10-Q 05/19/2020 - 10-Q 08/19/2020 - 10-Q 11/17/2020 - 10-Q 05/24/2021 - 10-Q 08/23/2021 - 10-Q